Characterization of antigenic peptides presented by HLA-B44 molecules on tumor cells expressing the gene MAGE-3

Katharina Fleischhauer, Doriana Fruci, Peter Van Endert, Jean Herman, Silvia Tanzarella, Hans J. Wallny, Pierre Coulie, Claudio Bordignon, Catia Traversari

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

The amino acid sequence of the protein encoded by the gene MAGE-3 was screened for peptides containing the binding motif for HLA-B44. Nine peptides were synthesized, and their binding affinity for HLA-B*4402 and -B*4403 was analyzed in an HLA class I α-chain refolding assay. Four peptides with binding affinity for HLA-B*4403 were chosen for in vitro cytotoxic T-lymphocyte induction assays using as antigen-presenting cells peptide-pulsed, autologous activated B lymphoblasts from a healthy, B*4403+ donor. Peptide-specific effecters could be raised only against one peptide, M3-167. Cytotoxic T lymphocytes specific for this peptide were also able to recognize melanoma cell lines expressing HLA-B44 and the gene MAGE-3, strongly suggesting that M3-167 is a naturally processed MAGE-3-encoded epitope presented by HLA-B44. M3-167 is a 1 amino acid N-terminal extension of M3-168, a naturally processed epitope MAGE-3-encoded epitope presented by HLA-A1 that has been previously described. TAP binding studies of these 2 peptides revealed that the TAP affinity of M3-167 is about 9-fold higher than that of M3-168. M3-167 or a longer precursor could be transported into the endoplasmatic reticulum, where it could be trimmed for presentation by HLA-A1 or -B44 molecules. Taken together, our data suggest that M3-167 could be an immunodominant peptide encoded by the gene MAGE-3.

Original languageEnglish
Pages (from-to)622-628
Number of pages7
JournalInternational Journal of Cancer
Volume68
Issue number5
DOIs
Publication statusPublished - 1996

Fingerprint

HLA-B44 Antigen
Peptides
Genes
Neoplasms
HLA-A1 Antigen
Epitopes
HLA-B Antigens
trypsinogen activation peptide
Cytotoxic T-Lymphocytes
Reticulum
Antigen-Presenting Cells
Amino Acid Sequence
Melanoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Characterization of antigenic peptides presented by HLA-B44 molecules on tumor cells expressing the gene MAGE-3. / Fleischhauer, Katharina; Fruci, Doriana; Van Endert, Peter; Herman, Jean; Tanzarella, Silvia; Wallny, Hans J.; Coulie, Pierre; Bordignon, Claudio; Traversari, Catia.

In: International Journal of Cancer, Vol. 68, No. 5, 1996, p. 622-628.

Research output: Contribution to journalArticle

Fleischhauer, Katharina ; Fruci, Doriana ; Van Endert, Peter ; Herman, Jean ; Tanzarella, Silvia ; Wallny, Hans J. ; Coulie, Pierre ; Bordignon, Claudio ; Traversari, Catia. / Characterization of antigenic peptides presented by HLA-B44 molecules on tumor cells expressing the gene MAGE-3. In: International Journal of Cancer. 1996 ; Vol. 68, No. 5. pp. 622-628.
@article{4ebe7ecc3ce642a59e97a37941176fa8,
title = "Characterization of antigenic peptides presented by HLA-B44 molecules on tumor cells expressing the gene MAGE-3",
abstract = "The amino acid sequence of the protein encoded by the gene MAGE-3 was screened for peptides containing the binding motif for HLA-B44. Nine peptides were synthesized, and their binding affinity for HLA-B*4402 and -B*4403 was analyzed in an HLA class I α-chain refolding assay. Four peptides with binding affinity for HLA-B*4403 were chosen for in vitro cytotoxic T-lymphocyte induction assays using as antigen-presenting cells peptide-pulsed, autologous activated B lymphoblasts from a healthy, B*4403+ donor. Peptide-specific effecters could be raised only against one peptide, M3-167. Cytotoxic T lymphocytes specific for this peptide were also able to recognize melanoma cell lines expressing HLA-B44 and the gene MAGE-3, strongly suggesting that M3-167 is a naturally processed MAGE-3-encoded epitope presented by HLA-B44. M3-167 is a 1 amino acid N-terminal extension of M3-168, a naturally processed epitope MAGE-3-encoded epitope presented by HLA-A1 that has been previously described. TAP binding studies of these 2 peptides revealed that the TAP affinity of M3-167 is about 9-fold higher than that of M3-168. M3-167 or a longer precursor could be transported into the endoplasmatic reticulum, where it could be trimmed for presentation by HLA-A1 or -B44 molecules. Taken together, our data suggest that M3-167 could be an immunodominant peptide encoded by the gene MAGE-3.",
author = "Katharina Fleischhauer and Doriana Fruci and {Van Endert}, Peter and Jean Herman and Silvia Tanzarella and Wallny, {Hans J.} and Pierre Coulie and Claudio Bordignon and Catia Traversari",
year = "1996",
doi = "10.1002/(SICI)1097-0215(19961127)68:5<622::AID-IJC12>3.0.CO;2-3",
language = "English",
volume = "68",
pages = "622--628",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "5",

}

TY - JOUR

T1 - Characterization of antigenic peptides presented by HLA-B44 molecules on tumor cells expressing the gene MAGE-3

AU - Fleischhauer, Katharina

AU - Fruci, Doriana

AU - Van Endert, Peter

AU - Herman, Jean

AU - Tanzarella, Silvia

AU - Wallny, Hans J.

AU - Coulie, Pierre

AU - Bordignon, Claudio

AU - Traversari, Catia

PY - 1996

Y1 - 1996

N2 - The amino acid sequence of the protein encoded by the gene MAGE-3 was screened for peptides containing the binding motif for HLA-B44. Nine peptides were synthesized, and their binding affinity for HLA-B*4402 and -B*4403 was analyzed in an HLA class I α-chain refolding assay. Four peptides with binding affinity for HLA-B*4403 were chosen for in vitro cytotoxic T-lymphocyte induction assays using as antigen-presenting cells peptide-pulsed, autologous activated B lymphoblasts from a healthy, B*4403+ donor. Peptide-specific effecters could be raised only against one peptide, M3-167. Cytotoxic T lymphocytes specific for this peptide were also able to recognize melanoma cell lines expressing HLA-B44 and the gene MAGE-3, strongly suggesting that M3-167 is a naturally processed MAGE-3-encoded epitope presented by HLA-B44. M3-167 is a 1 amino acid N-terminal extension of M3-168, a naturally processed epitope MAGE-3-encoded epitope presented by HLA-A1 that has been previously described. TAP binding studies of these 2 peptides revealed that the TAP affinity of M3-167 is about 9-fold higher than that of M3-168. M3-167 or a longer precursor could be transported into the endoplasmatic reticulum, where it could be trimmed for presentation by HLA-A1 or -B44 molecules. Taken together, our data suggest that M3-167 could be an immunodominant peptide encoded by the gene MAGE-3.

AB - The amino acid sequence of the protein encoded by the gene MAGE-3 was screened for peptides containing the binding motif for HLA-B44. Nine peptides were synthesized, and their binding affinity for HLA-B*4402 and -B*4403 was analyzed in an HLA class I α-chain refolding assay. Four peptides with binding affinity for HLA-B*4403 were chosen for in vitro cytotoxic T-lymphocyte induction assays using as antigen-presenting cells peptide-pulsed, autologous activated B lymphoblasts from a healthy, B*4403+ donor. Peptide-specific effecters could be raised only against one peptide, M3-167. Cytotoxic T lymphocytes specific for this peptide were also able to recognize melanoma cell lines expressing HLA-B44 and the gene MAGE-3, strongly suggesting that M3-167 is a naturally processed MAGE-3-encoded epitope presented by HLA-B44. M3-167 is a 1 amino acid N-terminal extension of M3-168, a naturally processed epitope MAGE-3-encoded epitope presented by HLA-A1 that has been previously described. TAP binding studies of these 2 peptides revealed that the TAP affinity of M3-167 is about 9-fold higher than that of M3-168. M3-167 or a longer precursor could be transported into the endoplasmatic reticulum, where it could be trimmed for presentation by HLA-A1 or -B44 molecules. Taken together, our data suggest that M3-167 could be an immunodominant peptide encoded by the gene MAGE-3.

UR - http://www.scopus.com/inward/record.url?scp=0029852657&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029852657&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0215(19961127)68:5<622::AID-IJC12>3.0.CO;2-3

DO - 10.1002/(SICI)1097-0215(19961127)68:5<622::AID-IJC12>3.0.CO;2-3

M3 - Article

C2 - 8938145

AN - SCOPUS:0029852657

VL - 68

SP - 622

EP - 628

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 5

ER -